Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Trial Profile

Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Doxorubicin; Ethiodized oil; Streptozocin
  • Indications Bone metastases; Cancer metastases; Colon cancer; Gastric cancer; Intestinal cancer; Liver metastases; Neuroendocrine tumours; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms EVACEL; FFCD 1104-EVACEL-GTE
  • Most Recent Events

    • 27 Mar 2020 Status changed from active, no longer recruiting to completed.
    • 31 Oct 2019 Results (n=74) assessing efficacy and tolerability of Everolimus as treatment liver metastases from digestive endocrine tumors post to embolization or chemoembolization, published in the European Journal of Cancer.
    • 31 Oct 2019 Primary endpoint (Rate of hepatic progression free survival at 24 months) has not been met as per results published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top